Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Conditions

Polycystic Ovary Syndrome 3Infertility 1Anovulation 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Glycoprotein Hormones, alpha Subunit × Clear all
NCT01653743 2016-01-07

Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
81 enrolled 11 charts

Anovulation, Polycystic Ovary Syndrome

NCT01081626 2014-02-13

Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

Merck KGaA, Darmstadt, Germany

Phase 4 Completed
310 enrolled 18 charts

Infertility, Polycystic Ovary Syndrome

NCT01185704 2014-02-13

ATTAC-PCO

Merck KGaA, Darmstadt, Germany

Phase 3 Completed
136 enrolled 21 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡